CG Oncology, Inc. Common stock (CGON) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in Irvine, DE, United States. Der aktuelle CEO ist Arthur Kuan.
CGON hat IPO-Datum 2024-01-25, 113 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $5.68B.
CG Oncology Inc is a clinical biopharmaceutical company developing innovative therapies for bladder cancer treatment. The company's lead product candidate, cretostimogene, is designed as a bladder-sparing therapeutic in clinical development for high-risk non-muscle invasive bladder cancer patients who have failed to respond to BCG immunotherapy, the current standard treatment. CG Oncology aims to address a significant unmet medical need in oncology by offering an alternative treatment option for BCG-unresponsive patients and positioning cretostimogene as a potential backbone therapy for bladder cancer management.
